Results 111 to 120 of about 31,538 (351)
Hemostaattisten tuotteiden käyttö sairaalan ulkopuolisessa ensihoidossa [PDF]
, 2011 Opinnäytetyö tehtiin hemostaattisten tuotteiden käytöstä sairaalan ulkopuolisessa ensihoidossa. Työssä tarkoituksena oli selvittää kyselyllä, kuinka laajassa käytössä hemostaattiset tuotteet Suomessa ovat ja millaisia kokemuksia ensihoidossa toimivilla
Lahtinen, Juho, Nordlund, Tuuve
core
Secondary Hematoma Expansion and Perihemorrhagic Edema after Intracerebral Hemorrhage: From Bench Work to Practical Aspects. [PDF]
, 2017 Intracerebral hemorrhages (ICH) represent about 10-15% of all strokes per year in the United States alone. Key variables influencing the long-term outcome after ICH are hematoma size and growth.
Lim-Hing, Krista, Rincon, Fred
core +2 more sources
American Journal of Hematology, EarlyView.ABSTRACT Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a
Bruno Fattizzo +38 more
wiley +1 more source
Cerebrovascular complications and infective endocarditis. impact of available evidence on clinical outcome [PDF]
, 2018 Infective endocarditis (IE) is a life-threatening disease. Its epidemiological profile has substantially changed in recent years although 1-year mortality is still high.
De Bellis, Antonio +8 more
core +1 more source
American Journal of Hematology, EarlyView.ABSTRACT Renal impairment (RI), defined as estimated glomerular filtration rate less than 60 mL/min with or without the need for dialysis, is a frequent and severe complication in patients with relapsed/refractory multiple myeloma (RRMM), as it can affect patient prognosis, drug metabolism and treatment options.
Ioannis Ntanasis‐Stathopoulos +7 more
wiley +1 more source
Evaluating the Efficacy and Safety of Hemofence (Thorombin Cross-Linked Sodium Hyaluronate Gel Matrix) in Hemostasis for Intractable Exudative Bleeding in Spinal Surgery: A Multicenter, Randomized, Phase III Clinical Trial [PDF]
NeurospineObjective To demonstrate the noninferiority of the novel hemostatic agent, Hemofence (BMI Korea Co., Ltd., thrombin cross-linked sodium hyaluronate gel matrix) compared to the established agent, Floseal Hemostatic Matrix (Baxter, thrombin-gelatin matrix)
Sungjae An +5 more
doaj +1 more source
Hemostatic Agents in Neurosurgery [PDF]
, 2012 Hemostasis comes from the coordinated activation of platelets and plasma clotting factors to form a platelet fibrin clot. Two processes, primary and secondary hemostasis activation of the clotting cascade id done by collagen for the intrinsic pathway, and the extrinsic pathway is activated by the release of tissue factors from the damaged zone. The two
Lapierre, F., D'Houtaud, S., Wager, M.
openaire +2 more sources
Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights
American Journal of Hematology, EarlyView.CTC offer a minimally invasive widow into systemic myeloma biology, overcoming the sampling bias of bone marrow biopsies. Their prognostic value at diagnosis, potential role in MRD monitoring, and ability to capture clonal evolution highlight them as actionable biomarkers for future precision medicine.
Benjamin Podvin +3 more
wiley +1 more source